<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03385239</url>
  </required_header>
  <id_info>
    <org_study_id>ISIS 678354-CS2</org_study_id>
    <nct_id>NCT03385239</nct_id>
  </id_info>
  <brief_title>Study of ISIS 678354 (AKCEA-APOCIII-LRx) in Patients With Hypertriglyceridemia and Established Cardiovascular Disease (CVD)</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Phase 2 Study of ISIS 678354 Administered Subcutaneously to Patients With Hypertriglyceridemia and Established Cardiovascular Disease (CVD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Akcea Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ionis Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Akcea Therapeutics</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, randomized, double-blind, placebo-controlled, dose-ranging study to
      evaluate the safety, including tolerability, of ISIS 678354 and to assess the efficacy of
      different doses and dosing regimens of ISIS 678354 for reduction of serum triglyceride (TG)
      levels in patients with hypertriglyceridemia and established CVD.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 5, 2018</start_date>
  <completion_date type="Anticipated">May 31, 2019</completion_date>
  <primary_completion_date type="Anticipated">January 31, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy of different doses and dosing regimens of ISIS 678354 on the reduction in serum triglyceride (TG) levels from baseline at the primary analysis time point.</measure>
    <time_frame>6 months</time_frame>
    <description>The comparison of percent change from baseline to primary analysis time point in fasting serum TG levels between ISIS 678354 treated groups and pooled placebo group.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The safety of ISIS 678354 by the incidence of treatment-emergent adverse events.</measure>
    <time_frame>6 months and 12 months</time_frame>
    <description>The safety of ISIS 678354 will be assessed by determining adverse effects by dose. Safety results in subjects dosed with ISIS 678354 will be compared with those from subjects dosed with placebo.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy of different doses and dosing regimens of ISIS 678354 on serum triglyceride (TG) levels from baseline at the primary analysis time point.</measure>
    <time_frame>6 months</time_frame>
    <description>The comparison of the proportion of patients who achieve serum TG ≤ 150 mg/dL, and the proportion of patients achieving TG ≤ 100 mg/dL as compared to placebo at the primary analysis time point.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the efficacy of ISIS 678354 on serum levels of apolipoprotein C-III (apoC-III).</measure>
    <time_frame>6 months</time_frame>
    <description>Percent change from baseline at the primary analysis time point in apoCIII will be compared between each ISIS 678354 treatment groups and pooled placebo group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the efficacy of ISIS 678354 on serum levels of cholesterol parameters.</measure>
    <time_frame>6 months</time_frame>
    <description>Percent change from baseline at the primary analysis time point in cholesterol parameters will be compared between each ISIS 678354 treatment groups and pooled placebo group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the efficacy of ISIS 678354 on serum levels of apolipoprotein B100 (apoB).</measure>
    <time_frame>6 months</time_frame>
    <description>Percent change from baseline at the primary analysis time point in apoB will be compared between each ISIS 678354 treatment groups and pooled placebo group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the efficacy of ISIS 678354 on serum levels of apolipoprotein A-1 (apoA-I).</measure>
    <time_frame>6 months</time_frame>
    <description>Percent change from baseline at the primary analysis time point in apoA-I will be compared between each ISIS 678354 treatment groups and pooled placebo group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Cmax of ISIS 678354 across different doses and dose regimens.</measure>
    <time_frame>6 months</time_frame>
    <description>Cmax of ISIS 678354 in plasma will be calculated for the treatment groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Tmax of ISIS 678354 across different doses and dose regimens.</measure>
    <time_frame>6 months</time_frame>
    <description>Tmax of ISIS 678354 in plasma will be calculated for the treatment groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma AUC values of ISIS 678354 across different doses and dose regimens.</measure>
    <time_frame>6 months</time_frame>
    <description>Plasma AUC values of ISIS 678354 will be calculated for the treatment groups.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Hypertriglyceridemia</condition>
  <condition>Cardiovascular Diseases</condition>
  <arm_group>
    <arm_group_label>ISIS 678354 Dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort A</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ISIS 678354 Dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort B</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ISIS 678354 Dose 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort C</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ISIS 678354 Dose 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort D</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Comparator: Placebo: Sterile Normal Saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Sterile Normal Saline (0.9% NaCl) by volume to match dose and regimen of active comparator depending on Cohort assignment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ISIS 678354</intervention_name>
    <description>Randomly assigned to one of the dosing cohorts</description>
    <arm_group_label>ISIS 678354 Dose 1</arm_group_label>
    <arm_group_label>ISIS 678354 Dose 2</arm_group_label>
    <arm_group_label>ISIS 678354 Dose 3</arm_group_label>
    <arm_group_label>ISIS 678354 Dose 4</arm_group_label>
    <other_name>AKCEA-APOCIII-LRx, IONIS-APOCIII-LRx</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Randomly assigned to one of the dosing cohorts. Dose of placebo in each cohort will match volume of active in that cohort.</description>
    <arm_group_label>Placebo Comparator: Placebo: Sterile Normal Saline</arm_group_label>
    <other_name>Sterile Normal Saline (0.9% NaCl)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Clinical diagnosis of CVD (defined as documented coronary artery disease, stroke, or
             peripheral artery disease

          -  Fasting serum TG ≥ 200 mg/dL (≥ 2.3 mmol/L) and ≤ 500 mg/dL (≥ 5.7 mmol/L) at
             Screening.

          -  Fasting TG ≥ 200 mg/dL and ≤ 500 mg/dL at Qualification visit.

          -  Must be on standard-of-care preventative therapy for known CVD risk factors

        Key Exclusion Criteria:

          -  Within 6 months of Screening: acute coronary syndrome, major cardiac surgery, or
             stroke/TIA

          -  Within 3 months of Screening: coronary, carotid, or peripheral arterial
             revascularization, major non-cardiac surgery, or lipoprotein apheresis

          -  Heart failure New York Heart Association (NYHA) class IV

          -  Type 1 diabetes mellitus

          -  Type 2 diabetes mellitus with any of the following:

               -  Newly diagnosed within 12 weeks of screening

               -  HbA1c ≥ 9.0% at Screening

               -  Recent change in anti-diabetic pharmacotherapy (change in dosage or addition of
                  new medication within 12 weeks of screening [with the exception of ± 10 units of
                  insulin

          -  BMI &gt; 40 kg/m2
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Akcea Therapeutics</last_name>
    <phone>617-207-0289</phone>
    <email>clinicalstudies@akceatx.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Clinical Site</name>
      <address>
        <city>Chicoutimi</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Principle Investigator</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 1, 2017</study_first_submitted>
  <study_first_submitted_qc>December 20, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 28, 2017</study_first_posted>
  <last_update_submitted>January 11, 2018</last_update_submitted>
  <last_update_submitted_qc>January 11, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 12, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>AKCEA-APOCIII-LRx</keyword>
  <keyword>IONIS-APOCIII-LRx</keyword>
  <keyword>Dyslipidemia</keyword>
  <keyword>Metabolic Disease</keyword>
  <keyword>Hyperlipidemia</keyword>
  <keyword>Cardiac Disease</keyword>
  <keyword>Lipid Metabolism Disorders</keyword>
  <keyword>Triglycerides High</keyword>
  <keyword>Vascular Diseases</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Hypertriglyceridemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

